Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA. Data on cariprazine, an investigational antipsychotic agent, provides details from Phase 3 trials for schizophrenia and acute mania in bipolar I disorder, as well as a long-term safety and tolerability open-label study in patients with bipolar I disorder. Separately, data on levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD), includes additional analyses of phase 3 trial results. Forest anticipates decisions from the FDA on both cariprazine and levomilnacipran within the calendar year.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA. Data on cariprazine, an investigational antipsychotic agent, provides details from Phase 3 trials for schizophrenia and acute mania in bipolar I disorder, as well as a long-term safety and tolerability open-label study in patients with bipolar I disorder. Separately, data on levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD), includes additional analyses of phase 3 trial results. Forest anticipates decisions from the FDA on both cariprazine and levomilnacipran within the calendar year.
Help employers find you! Check out all the jobs and post your resume.
